Mitochondria generate the majority of cellular ATP and are essential for neuronal function. Loss of mitochondrial activity leads to primary mitochondrial diseases and may contribute to neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Mitochondria communicate with the cell through mitochondrial retrograde signaling pathways. These signaling pathways are triggered by mitochondrial dysfunction and allow the organelle to control nuclear gene transcription. Neuronal mitochondrial retrograde signaling pathways have been identified in disease model systems and targeted to restore neuronal function and prevent neurodegeneration. In this review, we describe yeast and mammalian cellular models that have paved the way in the investigation of mitochondrial retrograde mechanisms. We then discuss the evidence for retrograde signaling in neurons and our current knowledge of retrograde signaling mechanisms in neuronal model systems. We argue that targeting mitochondrial retrograde pathways has the potential to lead to novel treatments for neurological diseases.
Mitochondria generate the majority of cellular ATP and are essential for neuronal function. Loss of mitochondrial activity leads to primary mitochondrial diseases and may contribute to neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Mitochondria communicate with the cell through mitochondrial retrograde signaling pathways. These signaling pathways are triggered by mitochondrial dysfunction and allow the organelle to control nuclear gene transcription. Neuronal mitochondrial retrograde signaling pathways have been identified in disease model systems and targeted to restore neuronal function and prevent neurodegeneration. In this review, we describe yeast and mammalian cellular models that have paved the way in the investigation of mitochondrial retrograde mechanisms. We then discuss the evidence for retrograde signaling in neurons and our current knowledge of retrograde signaling mechanisms in neuronal model systems. We argue that targeting mitochondrial retrograde pathways has the potential to lead to novel treatments for neurological diseases.
Keywords: mitochondria; retrograde; signaling Mitochondria are vital organelles at the heart of cellular metabolism. Mitochondria generate ATP through the action of three interlinked processes, b-oxidation of fatty acids, the tricarboxylic acid cycle (TCA) and oxidative phosphorylation (OXPHOS) (Fig. 1A) . b-Oxidation and the TCA cycle generate the reduced electron donors NADH and FADH 2, which are utilized by the electron transport chain (ETC). The ETC consists of four mitochondrial inner membrane protein complexes (Fig. 1B) : NADH-ubiquinone oxidoreductase (complex I), made up of 44 subunits, succinate-ubiquinone oxidoreductase (complex II), made up of four subunits, coenzyme Q reductase (complex III), made up of 11 subunits and the 14 subunit cytochrome c oxidase complex (complex IV) [1] . The lipophilic molecule ubiquinone and the small haem protein cytochrome c transfer electrons between the complexes in the inner membrane (Fig. 1B) . Protons pumped into the intermembrane space by OXPHOS complexes I, III, and IV generate an electrochemical gradient (DΨ) that is used by the 19-subunit ATP synthase (complex V) to generate the majority of cellular ATP (Fig. 1A,B) [2]. Movement of protons through the FO transmembrane domain of complex V causes rotation of the large F1 enzymatic domain, catalyzing the conversion of ADP to ATP [3, 4] . In addition to ATP synthesis, mitochondria also have key roles in amino acid biosynthesis, Ca 2+ buffering, iron-sulfur cluster synthesis, generation of reactive oxygen species (ROS), and apoptosis ( Fig. 1A ) [5] .
Mutations in genes encoding mitochondrial proteins, or in genes encoding proteins impinging on mitochondrial function, cause primary mitochondrial diseases. Mitochondrial diseases are rare at birth, but potentially affect up to 1 in 4300 in the population [6] . Although mitochondrial diseases are clinically heterogeneous they frequently affect the nervous system [7] .
The reason for this is thought to be due to the high energetic requirement of neurons, making them particularly dependent on efficient mitochondrial function. The clinical features of mitochondrial disease can be severe and early onset, such as developmental delay, encephalomyopathy and death in infancy in Leigh syndrome [8] . Conversely, mitochondrial disease can be adult onset and the clinical features more restricted, such as weakness of the external eye muscles and exercise intolerance in progressive external ophthalmoplegia [9] . The cause of the heterogeneity of the clinical features in mitochondrial diseases remains largely an enigma.
Mitochondrial dysfunction is also believed to contribute to late onset neurodegenerative disease. Parkinsonism has been reported in patients with mutations in the mitochondrial fusion gene OPA1 and the mitochondrial DNA polymerase gene POLG [10] [11] [12] . Juvenile forms of Parkinson's can be caused by mutations in the genes PINK1 and Parkin, which are involved in mitochondrial quality control, and loss of complex I activity in dopaminergic neurons in the substantia nigra pars compacta is a hallmark of sporadic late onset Parkinson's disease [13] [14] [15] [16] . Altered mitochondrial morphology, decreased respiratory complex I activity, and reduced mitochondrial DNA (mtDNA) levels are observed in the cortex of Alzheimer's disease patients [17] [18] [19] . Mitochondrial dysfunction is also observed in Alzheimer's mouse models, where it precedes neuronal cell loss [20, 21] .
Current evidence suggests that mitochondria evolved through endosymbiosis of an alpha-proteobacterium within an archaebacterial host cell [22] . This endosymbiotic event may in fact be the defining feature in the evolution of eukaryotes [23] . In the two billion years since this endosymbiotic event, mitochondria have become inextricably woven into the fabric of eukaryotic cells. Most cells contain hundreds to thousands of mitochondria, making up a fifth of cell volume [24] , which have evolved into a dynamic network that continually divides and fuses [25] . The vast majority of mitochondrial genes are now found in the nuclear genome, with only 37, 13 of which encode critical OXPHOS proteins, found in the mtDNA. buffering, iron-sulfur cluster synthesis, generation of ROS, and apoptosis. (B) Generation of ATP by the mitochondrial respiratory chain consisting of four OXPHOS complexes and ATP synthase (complex V). The TCA cycle provides NADH and FADH 2 to complexes I and II, respectively. OM, outer membrane; IM, inner membrane; IMS, intermembrane space; Q, ubiquinone; Cyt C, cytochrome c.
Mitochondrial biogenesis therefore occurs largely through the action of proteins encoded by the nuclear genome [26] . 'Anterograde regulation' of the mitochondrion by the nuclear genome is coordinated by several nuclear transcription factors, including PGC1-a, NRF1, and NRF2, which regulate the expression of proteins that are localized to mitochondria.
With its multifaceted role in cellular homeostasis, the ability of the mitochondrion to communicate with the host cell is vital. The idea of mitochondria as 'signaling organelles' encapsulates their ability to modify cellular processes as a result of alterations in mitochondrial function [27] . Mitochondrial signaling was first discovered in yeast, but analogous processes have subsequently been observed in higher eukaryotes [27] [28] [29] [30] . 'Mitochondrial retrograde signaling' pathways enable mitochondria to communicate with the nucleus to alter nuclear gene expression (Fig. 2) [31]. Excitingly, recent studies have shown that modulation of mitochondrial retrograde signaling has therapeutic potential in a range of diseases linked to mitochondrial dysfunction.
In this review, we use 'mitochondrial retrograde signaling' to describe mechanisms activated when altered mitochondrial function leads directly to changes in nuclear gene expression. We firstly describe the mechanisms involved in mitochondrial retrograde signaling that have been identified in yeast and animal model systems. We then discuss the importance of understanding retrograde signaling in neurons. We focus on our current understanding of retrograde signaling in the nervous system and the recent studies that have identified retrograde mechanisms in neurons. Finally, we discuss how targeting retrograde mechanisms has the potential to treat a range of neurological diseases and propose avenues for future research into the basic mechanisms involved.
Mitochondrial retrograde signaling in yeast
The Rtg pathway
The phenomenon of retrograde signaling was identified in a landmark paper from the Butow laboratory in 1987. Subtractive hybridization of cDNAs from yeast strains harboring mtDNA lesions uncovered variations in the abundance of nuclear-encoded mRNAs, both compared to controls and between different yeast mitochondrial dysfunction models [32] . Subsequent studies have focused on yeast rho 0 cellsan extreme form of mitochondrial dysfunction whereby mtDNA is entirely absent. In addition to ETC deficiency, the TCA cycle is not operational in rho 0 cells due to the compromised function of succinate dehydrogenase (complex II). The classical marker of retrograde signaling in yeast is upregulation of the peroxisomal isoform of citrate synthase (CIT2) [33] . CIT2 operates within the glyoxylate cycle, supplying citrate that can be oxidized to a-ketoglutarate by the first three enzymes of the TCA cycle. a-Ketoglutarate can subsequently be transaminated to glutamate, supplying the cells with nitrogen. In addition, the glyoxylate cycle permits the net synthesis of glucose from the b-oxidation of fatty acids; isocitrate is cleaved to form succinate and glyoxylate, the latter of which can undergo condensation with acetyl-CoA to form malate, and then ultimately glucose via gluconeogenesis. The retrograde response in yeast is coordinated by a heterodimer of two bHLH/ZIP transcription factors, Rtg1 and Rtg3, in concert with the histone acetyltransferase complex, SAGA-like (SLIK) [34, 37, 38] . Localization of Rtg1/Rtg3 is regulated by the putative phosphatase Rtg2 [39] . Rtg2 is also a core component of SLIK [38] , and therefore has a chromatin remodeling role in addition to promoting the partial dephosphorylation of Rtg3 and its consequent translocation to the nucleus in tandem with Rtg1. A wealth of positive and negative regulators act on the Rtg pathway; while bound to the 14-3-3 proteins Bmh1/2, the , from where they diffuse through the semiporous outer membrane into the cytosol. Both inhibition of the proteolytic activity of ClpP, and a haf-1 deletion mutant, decrease the induction of ubl-5, indicating a yet-to-be elucidated role for the effluxed peptides in the signal transduction of at least one UPR(mt) pathway.
ATFS-1 activity is controlled by organelle partitioning: it has both a nuclear localization sequence (NLS) within its C-terminal leucine zipper domain and an Nterminal mitochondrial targeting sequence (MTS). Under normal physiological conditions, ATFS-1 is imported into the mitochondrial matrix and degraded by the Lon protease. When the mitochondrial import machinery is compromised and/or HAF-1 is activated by upstream UPR(mt) components, mitochondrial import of ATFS-1 is impaired, and instead the protein accumulates in the nucleus and upregulates its target genes [47] .
UPR(mt) signaling in flies and mammals
The mammalian UPR(mt) presents a more complex picture. The pathways activated have proven to be myriad, dependent on cell and stress type. Pioneering work from the Hoogenraad lab established the ornithine transcarbamylase mutant (OTC-D) model of UPR(mt) induction and implicated the bZIP transcription factor CHOP in the UPR(mt) in COS-7 cells [51] . Subsequent work identified the redox signaling c-Jun/ JNK pathway in this model [55] . In many experimental paradigms, the UPR(mt) is cross-regulated with the integrated stress response (ISR). The ISR consists of four separate stress response signaling pathways that converge through regulation of phosphorylation of the translation initiation factor eIF2a [56] . In a murine intestinal epithelial cell model [57], the authors proposed a UPR(mt) pathway that placed ClpP-mediated proteolysis upstream of phosphorylation of c-Jun and eIF2a by the ISR kinase PKR. In Drosophila, induction of UPR(mt) chaperones and proteases could be abrogated by antioxidant enzymes, and produced by overexpression of the D-Jun and Relish (NF-jB) transcription factors [49] , lending weight to the idea that ROS may act downstream of unfolded protein stress in some branches of the UPR(mt). A UPR(mt) pathway that utilizes estrogen receptor activity and is unique to protein stress within the intermembrane space has been outlined in MCF-7 adenocarcinoma cells [58] .
Activating transcription factor 5 (ATF5) was recently proposed to regulate the mammalian UPR(mt) in a manner analogous to ATFS-1 in C. elegans [59] . A weak N-terminal MTS was identified in ATF5, in addition to its known NLS in the bZip domain. Expression of ATF5 is controlled by eIF2a, and hence at least in part by the ISR. Upregulation of HSP60, mtHSP70, and the protease LONP1 was abolished by knockdown of ATF5 in multiple HEK293T cell mitochondrial dysfunction models [59] . However, a recent a multiomics study of HeLa cell mitochondrial stress models identified the ISR as a key retrograde pathway, but failed to detect upregulation of UPR(mt) targets or ATF5 [60] .
Mitochondrial retrograde signaling in metazoans

Cell autonomous mitochondrial retrograde signaling
There are no obvious homologs of the yeast Rtg genes in metazoans. However, alterations in mitochondrial function lead directly to changes in nuclear gene expression in multicellular organisms. The pathways involved in these retrograde responses have been elucidated in a number of cellular models.
Cultured human hepatoma Hep3B cells were used as the first cellular model to demonstrate retrograde signaling in mammalian cells. Hypoxia activates a transcriptional response, via the transcription factor hypoxia inducible factor-1 alpha (HIF-1a), which coordinates gene expression to enhance oxygen delivery and glycolytic metabolism [61] . In Hep3B rho 0 cells (lacking mtDNA), hypoxia fails to activate the transcription of HIF-1a target genes [62] . Using a combination of OXPHOS inhibitors, ROS, likely generated from complex III, was shown to be necessary for this retrograde response via HIF-1a. This work therefore demonstrated that ROS, together with HIF-1a, act as a mitochondrial retrograde signaling pathway in mammalian cells.
Drug-induced mtDNA loss, or uncoupling of the ETC from ATP synthase in mouse myoblast C2C12 cells causes decreased apoptosis and increased tumor invasiveness in transplant models [30] . Loss of mitochondrial membrane potential in this model causes increased cytosolic Ca 2+ , resulting in activation of calcineurin [63] . Calcineurin activates NF-jB, which causes nuclear translocation of the REL-p50 heterodimer, where it associates with C/EBPd, CREB and NFAT in a nuclear enhanceosome complex to regulate gene expression [64] . Akt1 expression and activation is also increased by the retrograde response and is necessary for the phosphorylation and recruitment of heterogeneous ribonucleoprotein A2 (hnRNPA2) to the enhanceosome [65] . In this well-understood model, Ca 2+ -dependent mitochondrial retrograde signaling drives tumorigenesis. Retrograde signaling also promotes cell proliferation in human colorectal carcinoma cells through NF-jB, but in this context NF-jB activation is dependent on mitochondrial ROS rather than Ca 2+ as the proximal signal [66] . The A8344G mutation in the mtDNA tRNA Lys gene causes the mitochondrial disease 'MERRF' (myoclonus epilepsy and ragged red fibers). Cytoplasmic hybrid (cybrid) cells carrying the A8344G mutation, as well as osteosarcoma cells lacking mtDNA, show transcriptional changes indicating increased activity of the transcription factor CREB [67] . Activation of CREB is dependent on calcium/calmodulin kinase IV (CaM-KIV) activation caused by increased Ca 2+ concentration resulting from mitochondrial dysfunction. In this model CREB interacts with p53 to increase the expression of the cyclin-dependent kinase inhibitor p21. This retrograde mechanism reduces the rate of cell proliferation in response to mitochondrial dysfunction.
A number of nuclear proteins including ATFS-1, NF-jB, and p53 have been shown to accumulate in mitochondria [47, 68, 69] . Mutational analysis of 5-demethoxyubiquinone monooxygenase, known as CLK-1 in C. elegans and COQ7 in mammals, a mitochondrial enzyme that catalyses a critical step in the biosynthesis of ubiquinone, showed that it also localizes to the nucleus in both C. elegans and HeLa cells [70] . The nuclear localization of CLK-1/COQ7 is regulated by ROS levels and the nuclear pool plays a role in modulating cellular ROS. The regulated mitochondrial/nuclear localization of CLK-1 in C. elegans is reminiscent of ATFS-1, and nuclear CLK-1/COQ7 also modulates the expression of a subset of UPR(mt) genes. How CLK-1/COQ7 regulates gene expression in the nucleus is not clear, but it was shown through chromatin immunoprecipitation to bind specific gene regions in a ROS-regulated manner. Moreover, expression of a nuclear localized form of CLK-1 decreases the enhanced longevity phenotype associated with the clk-1 mutation. Although the functional consequences of nuclear COQ7 expression have not been tested in mammals, CLK-1/COQ7 mitochondrial retrograde signaling is clearly evolutionarily conserved.
Studies in Drosophila models have also identified retrograde signaling mechanisms. In the developing Drosophila eye, mutations in the complex I subunit Pdsw, or the complex IV subunit cytochrome c oxidase Va (CoVa) cause cell cycle arrest [71] . Inhibition of complex I, through loss of Pdsw, causes increased ROS and signaling via c-Jun N-terminal kinase and the transcription factor FoxO, to control the expression of the p27 homolog cell cycle regulator Dacapo. In contrast, defective complex IV activity, through loss of CoVa, causes activation of AMP kinase and the transcription factor p53, resulting in decreased expression of cyclin E. Both of these retrograde pathways promote cell cycle arrest in the proliferating epithelium of the developing Drosophila retina.
Increased expression of the transcription factor ATF4 is a frequently identified response to mitochondrial dysfunction in multicellular organisms [60, [72] [73] [74] [75] [76] [77] . Quiros et al. used acute pharmacological inhibition of mitochondrial function in HeLa cells with four different mitochondrial inhibitors, combined with transcriptomic, proteomic, and metabolomic analysis [60] . Identification of the ATF4-binding motif in regulated genes, as well as regulation of known ATF4 targets showed that ATF4 is a key regulator of the mitochondrial retrograde response in HeLa cells. ATF4 levels are controlled by eIF2a through preferential translation of upstream ORFs in the ATF4 5 0 UTR [78]. eIF2a is a target of both the endoplasmic reticulum (ER) UPR and the ISR, which regulates eIF2a phosphorylation through four independent kinases [56] . Inhibition of eIF2a abrogated the activation of ATF4 and its target genes in response to mitochondrial dysfunction. However, mitochondrial dysfunction did not affect other branches of the ER UPR and no single ISR kinase was necessary for the increased expression of ATF4 in response to mitochondrial dysfunction. Thus, the proximal mechanism by which mitochondrial dysfunction regulates eIF2a in this study was not established.
A related study, also using HeLa cells, found activation of eIF2a and increased ATF4 expression in response to loss of mitochondrial DNA, or treatment with doxycycline, which inhibits mitochondrial translation [76] . Similar to Quiros et al.
[60], several canonical transcriptional targets of the ER UPR were not regulated in response to mitochondrial dysfunction, suggesting the involvement of the ISR, but not the ER UPR. Knockdown of the four ISR kinases showed that eIF2a phosphorylation is mediated by GCN2 in response to doxycycline-mediated mitochondrial dysfunction. The mechanism leading from mitochondrial dysfunction to GCN2 is unknown. However, in C. elegans GCN2 is also required for the mitochondrial retrograde response in clk-1 mutants [79] . In the clk-1 model, mitochondrial-generated ROS are necessary and sufficient for GCN2 activation, implicating ROS as the proximal signal triggering the retrograde response via GCN2.
Mild mitochondrial dysfunction frequently extends lifespan in model systems. Using a genetic screen Lee et al. [80] found that C. elegans strains mutant for components of the ETC or complex V increase expression of target genes of the transcription factor HIF-1a in normoxic conditions. The mitochondrial retrograde response in these animals therefore acts in part through the activity of HIF-1a. Mutants that affect activity of complex I and complex III (clk-1 and isp-1) have increased lifespan, but this phenotype is reversed by knockdown of HIF-1a. ROS levels are increased in clk-1 and isp-1 mutants and the pro-oxidant paraquat increases lifespan in worms in a HIF-1a dependent manner. Thus, in C. elegans ROS is a major proximal signal for several mitochondrial retrograde responses that increase lifespan, acting either through HIF-1a, GCN2, or nuclear CLK-1 [70, 79, 80] . Interestingly, the activity of prolyl hydroxylases, which hydroxylate proline residues in HIF-1a leading to its degradation, is controlled by ROS and the TCA cycle intermediates 2-oxoglutarate (a-ketoglutarate) and succinate [81, 82] .
Mitochondrial retrograde signaling an important regulator of immune cell fate [81] . Activated CD4 + and CD8 + T cells increase mitochondrial mass, OXPHOS and ROS levels. Nuclear factor of activated T cells (NFAT) promotes T-cell activation, and inhibition of complex III activity prevents nuclear translocation of NFAT and expression of target genes, likely through a ROS-dependent mechanism [83] . Mitochondria are central players in metabolism and metabolic intermediates can act as retrograde signals in immune cells. Acetyl coenzyme A (acetyl-CoA), an abundant cytosolic metabolite and precursor to citrate in the TCA cycle, is required for histone acetyltransferase activity. Moreover, the TCA cycle intermediates a-ketoglutarate and succinate activate and inhibit histone demethylases, respectively [81] . T cells from mice with a T cell-specific knockout of lactate dehydrogenase A (LDHA) have reduced glycolysis and reduced cytosolic acetyl-CoA levels, likely due to increased metabolism of acetyl-CoA by the TCA cycle in mitochondria, resulting in decreased histone acetylation [84] . Thus, acetyl-CoA acts as a retrograde signal in T cells to modify target gene expression through the regulation of histone acetylation.
Overall these studies use a variety of in vitro and in vivo animal cellular models to investigate mitochondrial retrograde signaling. Although there is no canonical retrograde pathway as in yeast, the retrograde response is clearly active and is an important cellular signaling mechanism. The proximal signal emitted in response to mitochondrial dysfunction varies, but ROS and Ca 2+ are frequently implicated (Fig. 2) . The transcription factors targeted by these retrograde pathways include NF-jB, CREB, FoxO, and ATF4 (Fig. 2) . Regulation of ATF4 is predominant, acting downstream of the ISR.
Systemic mitochondrial retrograde signaling
Following from the original description in yeast, mitochondrial retrograde signaling has been studied largely as a cell autonomous phenomenon. However, recent discoveries have demonstrated that mitochondrial dysfunction in one tissue can result in a systemic signal that affects cells in distant parts of the animal.
The increased longevity caused by mild mitochondrial mutations in C. elegans provides a useful phenotype for dissecting the tissue-specificity of retrograde signals. Durieux et al. [85] used a C. elegans strain defective in the ability to transmit double-stranded RNA between cells to show that mild ETC inhibition, caused by cco-1 (COX4) RNAi, in either the intestine or nervous system is sufficient to extend lifespan. Mitochondrial dysfunction specifically activated the UPR(mt) and cco-1 RNAi in the nervous system caused cell nonautonomous activation of the UPR(mt) transcriptional response in the intestine. The signal responsible for this systemic retrograde response, termed 'mitokine', is yet to be identified in worms. In Drosophila, mild inhibition of complex I activity in muscle causes increased expression and secretion of ImpL2 (an ortholog of human insulin-like growth factor-binding protein 7, IGFBP7), which systemically inhibits insulin receptor pathway activity and increases lifespan [49] . Muscle-specific mitochondrial dysfunction in Drosophila results in a TGF-b-mediated retrograde response in adipose tissue as a result of increased systemic levels of the TGF-b ligand Activinb secreted from muscle tissue [86] .
In addition to the 37 standard genes, the mitochondrial genome contains at least two short open reading frames (sORFs) encoding mitochondrial-derived peptides that can exit the mitochondrion and can be secreted to have noncell autonomous functions. The sORF encoding the 24 amino acid humanin lies within the 16S ribosomal RNA mtDNA gene. Humanin is secreted from cells and is neuroprotective in Alzheimer's disease cellular models [87, 88] . A second sORF, located in the 12S ribosomal RNA mtDNA gene, encoding a 16-amino acid polypeptide called MOTS-c, is translated in the cytoplasm and has rapid wide-ranging effects on gene expression and metabolism in HEK293 cells [89] . MOTS-c overexpression causes dramatic activation of AMP kinase in cells and regular intraperitoneal injection of the MOTS-c peptide prevents high fat-induced obesity and insulin resistance in mice. Mitochondrial-derived peptides are an emerging class of mitochondrial retrograde signal that can have powerful cell autonomous and systemic effects.
Fibroblast growth factor 21 (FGF21) is a secreted FGF receptor ligand that has potent systemic effects on cellular metabolism. Serum FGF21 levels are increased in primary mitochondrial disease patients and in skeletal muscle and serum in mitochondrial disease animal models [90] [91] [92] . FGF21 expression exhibits the pattern of a classic mitochondrial retrograde response gene: in cultured myotubes treated with mitochondrial inhibitors, or transgenic mice with impaired mitochondrial function in skeletal muscle, FGF21 transcription is strongly upregulated [93] [94] [95] . Two mechanisms, the first involving the ISR via ATF4, and a second through p38 MAPK and direct regulation of ATF2, have been shown to regulate FGF21 expression in response to mitochondrial dysfunction in muscle [94, 95] . p38 MAPK phosphorylation and induction of FGF21 were also shown to be ROS-dependent upon mitochondrial dysfunction in myotubes [95] .
Growth differentiation factor 15 (GDF15) expression is a second retrograde-responsive secreted ligand that systemically regulates metabolism. GDF15 transcription and secretion are increased in mice with a muscle specific mutation in a mitochondrial ribosomal protein [96] . The increased release of FGF21 and GDF15, as a result of mitochondrial dysfunction in muscle, protects mice from diet induced obesity and insulin resistance.
Together these studies show that insulin sensitivity and metabolism are key targets of systemic mitochondrial retrograde signaling. Identification of the pathways involved and particularly of the secreted factors may provide new therapeutic strategies for diabetes, obesity, and metabolic syndrome.
Mitochondrial retrograde signaling in the nervous system
Is there a retrograde response in the nervous system and why is it important?
Retrograde signaling pathways have been described in a variety of cell culture systems and in vivo using C. elegans, Drosophila and mouse models. With the recent dramatic progress in the understanding of mitochondrial retrograde signaling it may at first seem unnecessary to study this process in the nervous system. Neurons are postmitotic, highly polarized and profoundly specialized cells. Neurons also work within an incomparably complex network of different neuronal and glial cell types. It cannot therefore be assumed that retrograde mechanisms active in proliferating or non-neuronal cells and tissues will be the same in the nervous system. Even when the mechanisms are conserved, the outcome of alterations in mitochondrial retrograde signaling will be different in neurons and potentially even vary between neuronal subtypes.
Understanding neuronal mitochondrial retrograde mechanisms is particularly important given the common neurological features of primary mitochondrial diseases and the contribution of mitochondrial dysfunction to sporadic neurodegenerative disease. The brain accounts for 2% of body weight, but around 20% of body energy expenditure [97] . The ability of neurons to fire actions potentials is dependent on the maintenance of a negative potential across the plasma membrane, which is generated by ATP-dependent Na + /K + pumps. Neurons also transport mitochondria great distances along axons and dendrites to provide local energy supplies and Ca 2+ buffering capacity at pre-and postsynapses. Retrograde signaling mechanisms need to be integrated with these vital roles of mitochondria in neuronal homeostasis. Recent studies with human-induced pluripotent stem cells and murine adult neural stem/progenitor cells have revealed that mitochondrial activity plays a critical role in neurogenesis and neuronal differentiation [98, 99] . Pharmacological and genetic inhibition of the ETC results in diminished neuronal differentiation, however, the contribution of mitochondrial retrograde signaling remains to be determined.
Transcriptional profiling has been used to document the retrograde response in primary neurons, cultured differentiated neurons and neuroblastoma cells. These studies observe rapid and diverse transcriptional responses to acute pharmacological inhibition of mitochondrial function, demonstrating that the retrograde response is active in neuronal cells [100] [101] [102] [103] [104] . Interestingly, upregulation of ATF4 signaling was the only significantly enriched network in analysis of differentiated dopaminergic neurons treated with the mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP+) [101] . Moreover, activation of the ER UPR is observed in several types of cultured neurons using a variety of drugs that acutely inhibit mitochondrial function as models of Parkinson's disease [100, 101, 103] .
The retrograde response to mitochondrial dysfunction has also been examined in the intact nervous system. Administration of the complex I inhibitors rotenone or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the substantia nigra, chemical lesion models of Parkinson's disease, cause altered expression of hundreds of genes [105, 106] . Treatment of mice with the mitochondrial uncoupling agent 2,4-dinitrophenol causes transcriptional alterations in a number of signaling pathways, including inhibition of mTOR signaling and increased ATF4 expression [107] . Panneuronal mitochondrial dysfunction in the Drosophila CNS also leads to altered expression of several hundred genes, some of which are targets of HIF-1a, indicative of a mitochondrial retrograde response [108] .
These studies clearly demonstrate that the mitochondrial retrograde response is activated in the nervous system. In some cases the responses may be related to those seen in non-neuronal systems, but identification of the underlying mechanisms and their effects on neuronal activity require functional studies.
Functional analyses of retrograde signaling pathways in the nervous system
Misregulation of mitochondrial retrograde signaling can have profound effects on neuronal activity and survival. Studies in animal models have investigated retrograde mechanisms in the nervous system and analyzed how these mechanisms control neuronal function and death.
Tumor necrosis factor receptor-associated Protein 1 (TRAP1) is a mitochondrially localized Hsp90 family chaperone. TRAP1 has several reported functions including interactions with cyclophilin D and Pink1 in mitochondria, as well as binding and inhibition of OXPHOS complex II [109] . Knockout of TRAP1 in Drosophila does not have overt effects on viability or mitochondrial activity, but causes increased ROS levels [110] . Surprisingly, genetic or pharmacological inhibition of TRAP1 suppresses the climbing defect and dopaminergic neuron loss seen in Pink1 mutant flies, which have increased ROS sensitivity. This suppression is dependent on the transcription factor FoxO, as FoxO mutations abrogate the beneficial effects of loss of TRAP1 in Pink1 flies. Loss of TRAP1 therefore has a protective role, and in the absence of TRAP1 increased ROS transmits a retrograde signal via FoxO to regulate nuclear gene transcription. A related retrograde pathway involving FoxO is also activated by inhibition of OXPHOS complex I activity and increased ROS in the Drosophila developing eye [71] .
Mitochondrial dysfunction induced by neuron-specific overexpression of the mitochondrial transcription factor TFAM or knockdown of a subunit of complex V in Drosophila causes defects in neuronal function, decreased redox potential, and reduced numbers of presynaptic mitochondria and active zones [108] . Transcriptomic analysis from the larval nervous system suggests that HIF-1a is an important regulator of the mitochondrial retrograde response in these models. Functional analysis confirmed this by showing strikingly that knockdown of HIF-1a alleviates the reduced neuronal function in Drosophila Leigh syndrome and Parkinson's models of mitochondrial dysfunction. HIF-1a is also functionally required for retrograde signaling in the clk-1 C. elegans longevity model [80] . Moreover, in the Ndufs4 Leigh syndrome mouse model, mild hypoxia, which stabilizes HIF-1a, has dramatic beneficial effects [111] . HIF-1a is therefore a major retrograde signaling target in aging and mitochondrial disease, although it's mechanism of regulation is yet to be determined.
As in cell culture models, the ATF4 stress response pathway is activated in several in vivo neuronal models of mitochondrial dysfunction. Overexpression of the mitochondrial protein Prel causes mitochondrial dysfunction and dendritic patterning defects in Drosophila peripheral larval sensory neurons [112] . Prel overexpression, as well as other types of mitochondrial dysfunction, cause increased phosphorylation of eIF2a in the brain. Knockdown of the eIF2a kinase PERK abrogates the dendritic loss phenotype caused by Prel overexpression, demonstrating that a mitochondrial retrograde response requiring PERK activity contributes to the phenotype. The ATF4 target gene CHOP has been shown to be a key mitochondrial retrograde target in the nervous system in mice. Mitochondrial dysfunction in mice caused by loss of the mitochondrial intermembrane space protein HtrA2, mutations in which have been found in Parkinson's patients, result in increased ROS and increased expression of genes including CHOP, indicative of ISR activation [113] .
The A1555G mutation in the mtDNA-encoded 12S rRNA gene causes nonsyndromic and/or aminoglycoside-induced deafness [114] . AMP kinase activation is a key retrograde signal in mammalian cells carrying the mtDNA A1555G mutation [115] . In this context, mitochondrial dysfunction causes ROSdependent signaling through AMP kinase and the transcription factor E2F1, and increased sensitivity to apoptosis. A1555G cells have increased phosphorylation of specific residues within the 12S rDNA and this can be modeled in mice by overexpression of the mitochondrial rRNA methyltransferase h-mtTFB1, resulting in progressive deafness. Spiral ganglion neurons degenerate in the inner ear in h-mtTFB1-overexpressing mice, but the deafness phenotype is less severe in h-mtTFB1-overexpressing mice that are heterozygous for E2F1, suggesting that retrograde signaling via E2F1 contributes to loss of spiral ganglion neurons.
These emerging functional studies have identified transcription factors including FoxO, HIF-1a, ATF4, and E2F1 as important players in neuronal mitochondrial retrograde signaling (Fig. 3) . They also demonstrate that constitutive activation of retrograde signaling leads to neuronal dysfunction and neurodegeneration (Fig. 3) .
Targeting mitochondrial retrograde signaling as a treatment for neurological disease
In yeast, activation of mitochondrial retrograde signaling reprograms the transcriptome to compensate for reduced glutamate biosynthesis. In contrast, in neurons, alterations in the transcriptome appear to have more diverse functions, including activation of several stress response pathways. A clear message from functional studies of neuronal retrograde pathways is that inhibition of the response frequently alleviates the defects in neuronal function or neurodegeneration. The mitochondrial retrograde response therefore promotes neuronal dysfunction and death in disease models and potentially in neurological disease patients (Fig. 3) . This observation seems counterintuitive, but may result from prolonged or permanent activation of pathways that evolved to deal with short-term alterations in mitochondrial function.
Studies in both Drosophila and mouse neuronal mitochondrial dysfunction models have shown that targeting retrograde signaling is beneficial. In Drosophila, inhibition of retrograde signaling (by knockdown of HIF-1a) prevents neuronal dysfunction and premature death caused by mitochondrial damage in neurons [108] . Knockdown of HIF-1a is also beneficial in Drosophila models of the mitochondrial disease Leigh syndrome and familial Parkinson's disease [108] . Interestingly, misregulation of HIF-1a has been proposed to contribute to the progression of Alzheimer's disease neuropathology [116] . Also in Drosophila, inhibition of eIF2a activation, by knockdown of PERK, abrogates the dendritic loss caused by mitochondrial dysfunction in sensory neurons [112] . In the HtrA2 mouse model of Parkinson's, inhibition of ISR signaling by knockout of CHOP is neuroprotective [113] . Knockout of CHOP, or another UPR factor ATF6, are also neuroprotective in neurotoxin induced models of Parkinson's [117] . In a transgenic mouse model of mitochondrial dysfunction-induced hearing loss, inhibition of retrograde signaling (in mice heterozygous for E2F1) improves hearing function [115] .
The core functions of mitochondria in the generation of ATP, metabolism of fatty acids, amino acid biosynthesis, Ca 2+ buffering, synthesis of iron-sulfur clusters and as gatekeepers of programmed cell death are undoubtedly crucial, and when perturbed contribute to human disease. However, it is clear that, at least in disease models, the ability of mitochondria to reprogram neurons through retrograde signaling can also contribute to the disease phenotype. Studies in models of human disease have shown that blocking retrograde signaling mechanisms can reverse pathological phenotypes. Applying this understanding will lead to new therapeutic approaches for a range of diseases that are currently lacking effective preventative treatments. Drugs that inhibit key regulators of mitochondrial retrograde signaling could be effective in primary mitochondrial diseases and also in common neurodegenerative conditions such as Alzheimer's and Parkinson's. Thus, there is a clear opportunity to exploit our knowledge of neuronal mitochondrial retrograde signaling to develop new disease-modifying strategies.
Conclusions and perspectives
The ability of mitochondria to communicate with the nucleus to affect gene transcription is highly conserved and active in neurons. Although studies of neuronal models began more recently than those in non-neuronal systems, there is clear evidence that retrograde signaling is functionally important in the nervous system. Diseases affecting the nervous system are some of the most complex and challenging to treat and new therapeutic strategies are desperately needed. Targeting the mitochondrial retrograde response has the potential to modify the underlying causes in a range of neurological diseases. For this to become a reality, animal models that closely replicate disease-relevant mitochondrial disorders are needed. Drosophila and mouse models of neuronal mitochondrial dysfunction have successfully identified and targeted retrograde pathways to alleviate the neurological phenotypes, using both genetic and pharmacological approaches [108, 111, 112, 115, 118] . In Drosophila, the Gal4/UAS system can be used to rapidly induce mitochondrial dysfunction in specific neuronal populations, or throughout the nervous system, either by overexpression or knockdown of key mitochondrial proteins. Neuronal-specific mouse models of mitochondrial disease include neuronal-specific knockouts of the complex I subunits NDUFS4, NDUFA5, the complex III subunit RISP, and the complex IV subunit COX10 [119] [120] [121] . Moreover, knockout of TFAM and expression of a mitochondrial-targeted restriction enzyme have both been used to target mitochondrial dysfunction to the nervous system [122, 123] . Future studies should aim to exploit these models to understand the retrograde response to different types of mitochondrial defect, both in the nervous system as a whole, and in different neuronal subtypes and neural networks.
Understanding the similarities and differences in retrograde signaling mechanisms triggered by different types of mitochondrial dysfunction in the nervous system is a major challenge. Studies using cells containing varying copy numbers of the A3243G mtDNA mutation, or completely lacking mtDNA, have shown that the transcriptional response varies according to the severity of mitochondrial dysfunction, even in the same cell type [124, 125] . The A3243G mutation in the mtDNA tRNA Leu gene causes the multiorgan mitochondrial disease 'MELAS' (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes). Four distinct transcriptional phases were observed in cells with increasing A3243G mutant mtDNA copy number [125] . Moreover, in the developing Drosophila eye, mutations in subunits of complex I and complex IV activate different retrograde pathways, even in the same tissue [71] . A more detailed understanding of the nature of mitochondrial dysfunction and its metabolic and molecular consequences in patients is clearly needed in order to effectively combat disease.
The most common proximal signals emitted by mitochondria as a retrograde response are ROS and Ca 2+ . Ca 2+ activates a transcriptional response via calcium-binding proteins and CAMK, whereas the mechanism by which ROS regulates gene expression is less well understood. Several transcriptional regulators have been identified in neuronal retrograde models, notably FoxO, HIF-1a, ATF4, and E2F1. Whether these mechanisms are specific to the respective model, or work in concert in response to neuronal mitochondrial dysfunction across different models, needs to be addressed.
Combining genetic models with multiomics and analysis of tissue from patients with defined mitochondrial lesions has provided profound insight into mitochondrial signaling mechanisms. In the coming years, these advances will continue to accelerate our understanding of the communication between mitochondria and the nucleus in the nervous system in normal physiology and pathological states. 
